Arrowhead Research | ARWR - Selling And Administration Expenses

Stock Price
71.26
Daily Change
1.93 2.78%
Monthly
7.34%
Yearly
258.45%
Q1 Forecast
67.19

Arrowhead Research reported $37.18M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Agios Pharmaceuticals USD 41.27M 4.6M Sep/2025
Alnylam Pharmaceuticals USD 262.59M 60.72M Sep/2025
Arrowhead Research USD 37.18M 6.23M Sep/2025
Incyte USD 329.08M 1.94M Sep/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
Ligand Pharmaceuticals USD 28.45M 8.27M Sep/2025
Merck USD 2.63B 0 Sep/2025
Moderna USD 268M 38M Sep/2025
Novartis USD 3.31B 134M Sep/2025
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
TG Therapeutics USD 63.37M 51.33M Sep/2025
Ultragenyx Pharmaceutical USD 86.62M 26K Sep/2025
Vertex Pharmaceuticals USD 445.1M 20.5M Sep/2025
Xencor USD 87.78M 72.66M Sep/2025